Table 1 Relationships between PIIN score and clinicopathological characteristics in patients with pancreatic cancer

Sex

3.443

0.064

  Male

24(68.6)

61(50.8)

  Female

11(31.4)

59(49.2)

Age (years)

3.425

0.064

  ≤ 63

18(51.4)

41(34.2)

  > 63

17(48.6)

79(65.8)

Tumor location

8.853

0.003

  Head

17(48.6)

90(75)

  Body/Tail

18(51.4)

30(25)

Lymphovascular invasion

2.544

0.111

  No

28(80)

79(65.8)

  Yes

7(20)

41(34.2)

Nerve invasion

0.501

0.479

  No

7(20)

18(15)

  Yes

28(80)

102(85)

Grade

0.092

0.762

  Well/moderate

15(42.9)

48(40)

  Poor/undifferentiated

20(57.1)

72(60)

Tumor size (cm)

0.158

0.691

  ≤ 3

15(42.9)

56(46.7)

  > 3

20(57.1)

64(53.3)

T stage

0.307

0.580

  T1/T2

24(68.6)

88(73.3)

  T3/T4

11(31.4)

32(26.7)

N stage

2.223

0.329

  N0

21(60.0)

60(50)

  N1

13(37.1)

48(40)

  N2

1(2.9)

12(10)

TNM stage

0.489

0.783

  I

14(40.0)

41(34.2)

  II

15(42.9)

59(49.2)

  III

6(17.1)

20(16.7)

CA 19 − 9 (U/ml)

1.731

0.421

  ≤ 91.2

15(42.9)

43(35.8)

  91.2-258.1

10(28.6)

28(23.3)

  > 258.1

10(28.6)

49(40.8)

Adjuvant chemotherapy

1.272

0.259

  No

12(34.3)

54(45)

  Yes

23(65.7)

66(55)

Type of adjuvant chemotherapy

0.924

0.820

  Gemcitabine

2(8.7)

10(15.2)

  Gemcitabine + Nab-Paclitaxel

5(21.7)

11(16.7)

  Tegafur

8(34.8)

25(37.9)

  Other chemotherapy regimen

8(34.8)

20(30.3)

  Chemotherapy completion rate

2.329

0.127

  Complete

14(60.9)

28(42.4)

  Incomplete

9(39.1)

38(57.6)

Postoperative complications

20.057

< 0.001

  No

9(25.7)

78(65)

  Yes

26(74.3)

42(35)

Type of postoperative complications

6.025

0.110

  Infection

10(38.5)

13(31)

  Bleeding

4(15.4)

5(11.9)

  Pancreatic leak

9(34.6)

8(19)

  Other complications

3(11.5)

16(38.1)